The purpose of this study is to compare short term (up to 48 hours) traditional cardiac
rhythm monitoring using a standard ambulatory Holter monitor versus long term (up to 14
days), continuous ambulatory cardiac rhythm monitoring using a new device cleared by the FDA
(Zio® Patch), iRhythm Technologies, Inc., San Francisco CA) in patients with suspected
Are being seen in the outpatient office for evaluation, treatment, or follow-up of arrhythmias;
Have a medical history for which ascertaining whether asymptomatic arrhythmias is occurring could be helpful in their treatment plan;
Are capable of giving informed consent; assessed by the investigator or the Study Coordinator;
Are 18 years of age or older;
Able to comply with long term continuous monitoring ECG device.
Have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives, psoriasis) as the Zio(R)Patch should not be used on patients with known skin allergies, conditions, or sensitivities; or
Are receiving pacing therapy (e.g., from a pacemaker); or
Are anticipated to receive or require external cardiac defibrillation during the monitoring period; or
Are anticipated to be exposed to high frequency surgical equipment during the monitoring period.